NOS3 and Hyperglycemia: Indeed, S18886, a potent TP inhibitor, effectively blocked the diabetes-related rise in lesion area, while not impacting hyperglycaemia or hypercholesterolaemia, and further prevented the decline in endothelial function and endothelial nitric oxide synthase expression, alongside the diabetes-linked increase in inflammation markers.